Tech Center 1600 • Art Units: 1618 1647
This examiner grants 81% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18535068 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | Non-Final OA | AMGEN INC. |
| 18169345 | ANTI-IL2 RECEPTOR GAMMA ANTIGEN-BINDING PROTEINS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18583340 | Compositions and Methods for Targeting Connexin Hemichannels | Non-Final OA | Board of Regents, The University of Texas System |
| 18043534 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | Non-Final OA | YALE UNIVERSITY |
| 18024143 | BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT AND INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT, AND USE THEREOF | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18587147 | BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS | Non-Final OA | The United States Government As Represented By the Department of Veterans Affairs |
| 18285135 | METHOD FOR PRODUCING IMMUNE CELL COMPOSITION | Non-Final OA | University of Ulsan Foundation for Industry Cooperation |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | Non-Final OA | St. Jude Children's Research Hospital, Inc. |
| 18552477 | ANTIGEN BINDING PROTEINS AND COMBINATIONS THEREOF | Non-Final OA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 18480730 | ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18023246 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF DIALYSIS PRURITUS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18032959 | METHODS OF TREATING PATIENTS HAVING COMPLEMENT DISORDERS USING ANTI-C5 ANTIBODIES | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18031940 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18543912 | PSGL-1 Antagonists and Uses Thereof | Non-Final OA | Five Prime Therapeutics, Inc. |
| 18284836 | Method for Construction of Nucleic Acid Self-Assembly-Mediated ADC Drug and Use Thereof | Non-Final OA | ASSEMBLY MEDICINE, LLC. |
| 18005752 | FUSION PROTEIN COMPRISING IGE FC RECEPTOR ALPHA SUBUNIT EXTRACELLULAR DOMAIN AND ANTI-IL-4R ANTIBODY, AND USE THEREOF | Non-Final OA | GI INNOVATION, INC. |
| 18034177 | CHIMERIC ANTIGEN RECEPTOR TARGETING CD7 AND USE THEREOF | Non-Final OA | BIOHENG THERAPEUTICS LIMITED |
| 17997241 | MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS | Non-Final OA | TENEOBIO, INC |
| 18027413 | ANTI-EPHA4 ANTIBODY | Non-Final OA | EISAI R&D MANAGEMENT CO., LTD. |
| 17999786 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18030203 | MEDICINE FOR TREATING CANCER | Non-Final OA | CHIOME BIOSCIENCE INC. |
| 18247628 | ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | Non-Final OA | Ardeagen Corporation |
| 18246756 | Antibody Binding to Human IL-33, Preparation Method Therefor, and Use Thereof | Non-Final OA | SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. |
| 18245691 | SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | BIOTHEUS INC. |
| 18043570 | ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE | Non-Final OA | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18021568 | ANTI-FACTOR XII (FXII) NANOBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF | Non-Final OA | NINGBO COMGEN BIOTECH CO., LTD. |
| 18017167 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | Non-Final OA | Dyne Therapeutics, lnc. |
| 18011764 | ANTIBODIES RECOGNIZING SORTILIN | Final Rejection | Tarlochan S. NIJJAR |
| 17765009 | CH1 DOMAIN VARIANTS ENGINEERED FOR PREFERENTIAL LIGHT CHAIN PAIRING AND MULTISPECIFIC ANTIBODIES COMPRISING THE SAME | Non-Final OA | ADIMAB, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy